Skip to main content
SpringerLink
Log in

Onychomycosis: Topical Therapy and Devices

  • Chapter
Scher and Daniel’s Nails

Abstract

Onychomycosis is a common condition and accounts for 50% of all nail diseases. Dermatophyte organisms are responsible for most cases of toenail onychomycosis, with Trichophyton rubrum and Trichophyton mentagrophytes, representing the first and second most commonly isolated organisms in the United States (US). Nondermatophyte molds, such as Fusarium and Acremonium and yeasts such as Candida parapsilosis are responsible for the remaining cases. This chapter will review treatment options for onychomycosis for adults and children, including nail avulsion, available topical therapies, as well as those in clinical trials. Lasers, photodynamic therapy, devices, such as non-thermal plasma, and over the counter treatments will also be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 84.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Scher RK, Rich P, Pariser D, Elewski B. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg. 2013;32(2 Suppl 1):S2–4.

    PubMed  Google Scholar 

  2. Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R, Taskforce on Onychomycosis E. Treatment options – development of consensus guidelines. J Eur Acad Dermatol Venereol JEADV. 2005;19(Suppl 1):25–33.

    PubMed  Google Scholar 

  3. Scher RK, Tosti A, Joseph WS, Vlahovic TC, Plasencia J, Markinson BC, et al. Onychomycosis diagnosis and management: perspectives from a joint dermatology-podiatry roundtable. J Drugs Dermatol JDD. 2015;14(9):1016–21.

    CAS  PubMed  Google Scholar 

  4. Feldstein S, Totri C, Friedlander SF. Antifungal therapy for onychomycosis in children. Clin Dermatol. 2015;33(3):333–9.

    PubMed  Google Scholar 

  5. Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol. 2014;7(7):10–8.

    PubMed  PubMed Central  Google Scholar 

  6. Stokes JH. Letter to referring physician – 1938. Int J Dermatol. 1999;38(11):827. 9, 40.

    CAS  PubMed  Google Scholar 

  7. Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol. 2013;31(5):544–54.

    PubMed  Google Scholar 

  8. Pandhi D, Verma P. Nail avulsion: indications and methods (surgical nail avulsion). Indian J Dermatol Venereol Leprol. 2012;78(3):299–308.

    PubMed  Google Scholar 

  9. Lai WY, Tang WY, Loo SK, Chan Y. Clinical characteristics and treatment outcomes of patients undergoing nail avulsion surgery for dystrophic nails. Hong Kong Med J (Xianggang yi xue za zhi/Hong Kong Acad Med). 2011;17(2):127–31.

    CAS  Google Scholar 

  10. Elewski B, Pariser D, Rich P, Scher RK. Current and emerging options in the treatment of onychomycosis. Semin Cutan Med Surg. 2013;32(2 Suppl 1):S9–12.

    PubMed  Google Scholar 

  11. Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol. 2003;149(Suppl 65):5–9.

    PubMed  Google Scholar 

  12. Flagothier C, Pierard-Franchimont C, Pierard GE. New insights into the effect of amorolfine nail lacquer. Mycoses. 2005;48(2):91–4.

    CAS  PubMed  Google Scholar 

  13. Gupta AK, Simpson FC. Routes of drug delivery into the nail apparatus: implications for the efficacy of topical nail solutions in onychomycosis. J Dermatolog Treat. 2015:1–3.

    Google Scholar 

  14. Polak A. Preclinical data and mode of action of amorolfine. Dermatology. 1992;184(Suppl 1):3–7.

    PubMed  Google Scholar 

  15. Insert AP. Amorolfine 5% W/V Nail Lacquer: Medicines and Healthcare Products Regulatory Agency; 2011. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con129125.pdf2011.

  16. Baran R, Sigurgeirsson B, de Berker D, Kaufmann R, Lecha M, Faergemann J, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol. 2007;157(1):149–57.

    CAS  PubMed  Google Scholar 

  17. Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther. 2006;28(12):1989–95.

    CAS  PubMed  Google Scholar 

  18. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol. 2000;43(4 Suppl):S57–69.

    CAS  PubMed  Google Scholar 

  19. Penlac. Package insert: Penlac nail lacquer (Ciclopirox) topical solution, 8%: Dermik Laboratories; 2004 [21 June 2014]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf2004.

  20. Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, Senda H, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600–8.

    CAS  PubMed  Google Scholar 

  21. Jublia. Package insert: Jublia (efinaconazole 10% solution) [June 26 2015]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf.

  22. Rock FL, Mao W, Yaremchuk A, Tukalo M, Crepin T, Zhou H, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007;316(5832):1759–61.

    CAS  PubMed  Google Scholar 

  23. Elewski BE, Aly R, Baldwin SL, Gonzalez Soto RF, Rich P, Weisfeld M, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62–9.

    CAS  PubMed  Google Scholar 

  24. Kerydin. Package insert: Kerydin (tavaborole) topical solution, 5% [June 26 2015]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204427s000lbl.pdf.

  25. Elewski BE, Ghannoum MA, Mayser P, Gupta AK, Korting HC, Shouey RJ, et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol JEADV. 2013;27(3):287–94.

    CAS  PubMed  Google Scholar 

  26. Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses. 2014;57:389–93.

    CAS  PubMed  Google Scholar 

  27. Wiederhold NP, Fothergill AW, McCarthy DI, Tavakkol A. Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis. Antimicrob Agents Chemother. 2014;58(6):3553–5.

    PubMed  PubMed Central  Google Scholar 

  28. Trial C. Safety and efficacy of luliconazole solution, 10% in subjects with mild to moderate onychomycosis (SOLUTION): Topica Pharmaceuticals; 2013 [21 June 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT01431820.

  29. Gupta AK, Sibbald RG, Lynde CW, Hull PR, Prussick R, Shear NH, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol. 1997;36(3 Pt 1):395–402.

    CAS  PubMed  Google Scholar 

  30. Leibovici V, Evron R, Dunchin M, Westerman M, Ingber A. A population-based study of toenail onychomycosis in Israeli children. Pediatr Dermatol. 2009;26(1):95–7.

    PubMed  Google Scholar 

  31. Singal A, Khanna D. Onychomycosis: diagnosis and management. Indian J Dermatol Venereol Leprol. 2011;77(6):659–72.

    PubMed  Google Scholar 

  32. Friedlander SF, Chan YC, Chan YH, Eichenfield LF. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. Pediatr Dermatol. 2013;30(3):316–22.

    PubMed  Google Scholar 

  33. Pena-Penabad C, Garcia-Silva J, Almagro M, del Pozo J, Fonseca E. Superficial white onychomycosis in a 3-year-old human immunodeficiency virus-infected child. J Eur Acad Dermatol Venereol JEADV. 2001;15(1):51–3.

    CAS  PubMed  Google Scholar 

  34. Hsu MM. Rapid response of distal subungual onychomycosis to 5% amorolfine nail lacquer in a 20-month-old healthy infant. Pediatr Dermatol. 2006;23(4):410–1.

    PubMed  Google Scholar 

  35. Liddell LT, Rosen T. Laser therapy for onychomycosis: fact or fiction? J Fungi. 2015;1(1):44–54.

    Google Scholar 

  36. Choi MJ, Zheng Z, Goo B, Cho SB. Antifungal effects of a 1444-nm neodymium:yttrium-aluminum-garnet laser on onychomycosis: a pilot study. J Dermatolog Treat. 2014;25(4):294–7.

    CAS  PubMed  Google Scholar 

  37. Carney C, Cantrell W, Warner J, Elewski B. Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser. J Am Acad Dermatol. 2013;69(4):578–82.

    PubMed  Google Scholar 

  38. Hochman LG. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. J Cosmet Laser Ther. 2011;13(1):2–5.

    PubMed  Google Scholar 

  39. Kimura U, Takeuchi K, Kinoshita A, Takamori K, Hiruma M, Suga Y. Treating onychomycoses of the toenail: clinical efficacy of the sub-millisecond 1,064 nm Nd: YAG laser using a 5 mm spot diameter. J Drugs Dermatol: JDD. 2012;11(4):496–504.

    CAS  PubMed  Google Scholar 

  40. Waibel J, Wulkan AJ, Rudnick A. Prospective efficacy and safety evaluation of laser treatments with real-time temperature feedback for fungal onychomycosis. J Drugs Dermatol: JDD. 2013;12(11):1237–42.

    PubMed  Google Scholar 

  41. Hollmig ST, Rahman Z, Henderson MT, Rotatori RM, Gladstone H, Tang JY. Lack of efficacy with 1064-nm neodymium:yttrium-aluminum-garnet laser for the treatment of onychomycosis: a randomized, controlled trial. J Am Acad Dermatol. 2014;70(5):911–7.

    PubMed  Google Scholar 

  42. Zhang RN, Wang DK, Zhuo FL, Duan XH, Zhang XY, Zhao JY. Long-pulse Nd:YAG 1064-nm laser treatment for onychomycosis. Chin Med J. 2012;125(18):3288–91.

    PubMed  Google Scholar 

  43. Moon SH, Hur H, Oh YJ, Choi KH, Kim JE, Ko JY, et al. Treatment of onychomycosis with a 1,064-nm long-pulsed Nd:YAG laser. J Cosmet Laser Ther. 2014;16(4):165–70.

    PubMed  Google Scholar 

  44. Noguchi H, Miyata K, Sugita T, Hiruma M, Hiruma M. Treatment of onychomycosis using a 1064nm Nd:YAG laser. Med Mycol J. 2013;54(4):333–9.

    PubMed  Google Scholar 

  45. Hees H, Jager MW, Raulin C. Treatment of onychomycosis using the 1 064 nm Nd:YAG laser: a clinical pilot study. J Ger Soc Dermatol JDDG (Journal der Deutschen Dermatologischen Gesellschaft). 2014;12(4):322–9.

    Google Scholar 

  46. Kalokasidis K, Onder M, Trakatelli MG, Richert B, Fritz K. The effect of Q-switched Nd:YAG 1064 nm/532 nm laser in the treatment of onychomycosis in vivo. Dermatol Res Pract. 2013;2013:379725.

    PubMed  PubMed Central  Google Scholar 

  47. Landsman AS, Robbins AH, Angelini PF, Wu CC, Cook J, Oster M, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc. 2010;100(3):166–77.

    PubMed  Google Scholar 

  48. Lim EH, Kim HR, Park YO, Lee Y, Seo YJ, Kim CD, et al. Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J Am Acad Dermatol. 2014;70(5):918–23.

    PubMed  Google Scholar 

  49. Heinemann IU, Jahn M, Jahn D. The biochemistry of heme biosynthesis. Arch Biochem Biophys. 2008;474(2):238–51.

    CAS  PubMed  Google Scholar 

  50. Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, Apalla Z, Ioannides D. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: preliminary results of a single-centre open trial. Acta Derm Venereol. 2010;90(2):216–7.

    PubMed  Google Scholar 

  51. Heinlin J, Maisch T, Zimmermann JL, Shimizu T, Holzmann T, Simon M, et al. Contact-free inactivation of Trichophyton rubrum and Microsporum canis by cold atmospheric plasma treatment. Future Microbiol. 2013;8(9):1097–106.

    CAS  PubMed  Google Scholar 

  52. Zemel M, Friedman G, Park S. Personal communication, in vitro nail studies with plasma. 2014.

    Google Scholar 

  53. Ouf SA, El-Adly AA, Mohamed AH. Inhibitory effect of silver nanoparticles mediated by atmospheric pressure air cold plasma jet against dermatophyte fungi. J Med Microbiol. 2015;64:1151–61.

    CAS  PubMed  Google Scholar 

  54. Lipner SR, Friedman G, Scher RK. Pilot study to evaluate a plasma device in the treatment of onychomycosis, submitted. 2015.

    Google Scholar 

  55. Halteh P, Lipner SR, Scher RK. Over the counter and natural remedies for onychomycosis: do they really work? Cutis, Accepted. 2015.

    Google Scholar 

  56. Jo Siu WJ, Tatsumi Y, Senda H, Pillai R, Nakamura T, Sone D, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013;57(4):1610–6.

    PubMed  PubMed Central  Google Scholar 

  57. Baker SJ, Zhang YK, Akama T, Lau A, Zhou H, Hernandez V, et al. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem. 2006;49(15):4447–50.

    CAS  PubMed  Google Scholar 

  58. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol. 2000;42(2 Pt 1):217–24.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Weill Cornell Medicine, New York, NY, USA

    Shari R. Lipner & Richard K. Scher

Authors
  1. Shari R. Lipner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard K. Scher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shari R. Lipner .

Editor information

Editors and Affiliations

  1. University of Pennsylvania, Philadelphia, PA, USA

    Adam I. Rubin

  2. Brown University, Providence, RI, USA

    Nathaniel J. Jellinek

  3. Department of Dermatology, University of Mississippi Medical Center, Jackson, MS, USA

    C. Ralph Daniel III

  4. Department of Dermatology, Weill Cornell Medical College, New York, NY, USA

    Richard K. Scher

11.1 Electronic Supplementary Materials

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Lipner, S.R., Scher, R.K. (2018). Onychomycosis: Topical Therapy and Devices. In: Rubin, A.I., Jellinek, N.J., Daniel, C.R., Scher, R.K. (eds) Scher and Daniel’s Nails. Springer, Cham. https://doi.org/10.1007/978-3-319-65649-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-65649-6_11

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-65647-2

  • Online ISBN: 978-3-319-65649-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation